Comparative Prime-Boost Vaccinations Using Semliki Forest Virus, Adenovirus, and ALVAC Vectors Demonstrate Differences in the Generation of a Protective Central Memory CTL Response against the P815 Tumor1

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Immunology

• Publication date

  2007-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.178.11.6761PMID 17513723
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer vaccines and immunotherapy

  2009cited by this paper
• Recombinant antibodies for cancer therapy

  2008influential reference
• Esophageal achalasia: Is the herpes simplex virus really innocent?

  2007cited by this paper
• Innate Inflammatory Signals Induced by Various Pathogens Differentially Dictate the IFN-I Dependence of CD8 T Cells for Clonal Expansion and Memory Formation1

  2006cited by this paper
• Developing and maintaining protective CD8+ memory T cells

  2006cited by this paper
• Cooperation between CD4+ and CD8+ T cells: when, where, and how.

  2006cited by this paper
• Viral vectors for cancer immunotherapy.

  2006cited by this paper
• Development, trafficking, and function of memory T‐cell subsets

  2006cited by this paper
• Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination.

  2006cited by this paper
• Humoral Responses against Coimmunized Protein Antigen but Not against Alphavirus-Encoded Antigens Require Alpha/Beta Interferon Signaling

  2006cited by this paper
• Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors

  2006cited by this paper
• Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100

  2006cited by this paper
• Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma

  2006cited by this paper
• Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.

  2006cited by this paper
• Adoptive immunotherapy for cancer: building on success

  2006cited by this paper
• RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5'-Phosphates

  2006cited by this paper
• Functional signatures of protective antiviral T‐cell immunity in human virus infections

  2006cited by this paper
• CD8+ T‐cell memory in tumor immunology and immunotherapy

  2006influential reference
• Predicting Tumor Outcome following Cancer Vaccination by Monitoring Quantitative and Qualitative CD8+ T Cell Parameters1

  2006cited by this paper
• Adenovirus as vehicle for anticancer genetic immunotherapy

  2005cited by this paper
• Efficient induction of T‐cell responses to carcinoembryonic antigen by a heterologous prime‐boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA

  2005cited by this paper
• Human tumor-specific T lymphocytes: does function matter more than number?

  2005cited by this paper
• Differential contributions of central and effector memory T cells to recall responses

  2005cited by this paper
• Functional Properties and Lineage Relationship of CD8+ T Cell Subsets Identified by Expression of IL-7 Receptor α and CD62L1

  2005cited by this paper
• [HIV vaccines].

  2005cited by this paper
• Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence

  2005cited by this paper
• Toll-like receptor 3 promotes cross-priming to virus-infected cells

  2005cited by this paper
• Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.

  2005cited by this paper
• Early Alpha/Beta Interferon Production by Myeloid Dendritic Cells in Response to UV-Inactivated Virus Requires Viral Entry and Interferon Regulatory Factor 3 but Not MyD88

  2005cited by this paper
• Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.

  2005cited by this paper
• Comparison of Two Cancer Vaccines Targeting Tyrosinase: Plasmid DNA and Recombinant Alphavirus Replicon Particles

  2005cited by this paper
• Adenoviral strategies for the gene therapy of cancer.

  2005cited by this paper
• Initial T cell frequency dictates memory CD8+ T cell lineage commitment

  2005cited by this paper
• Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.

  2005influential reference
• Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.

  2005cited by this paper
• Tumor vaccines

  2004cited by this paper
• Progress in DNA‐based heterologous prime‐boost immunization strategies for malaria

  2004cited by this paper
• Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.

  2004cited by this paper
• Gene-based vaccines and immunotherapeutics

  2004cited by this paper
• Induction of HIV Immunity in the Genital Tract After Intranasal Delivery of a MVA Vector: Enhanced Immunogenicity After DNA Prime-Modified Vaccinia Virus Ankara Boost Immunization Schedule 1

  2004cited by this paper
• Induction of P815 tumor immunity by DNA-based recombinant Semliki Forest virus or replicon DNA expressing the P1A gene.

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Central memory and effector memory T cell subsets: function, generation, and maintenance.

  2004cited by this paper
• Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen

  2004cited by this paper
• Carcinoembryonic antigen-based vaccines.

  2003cited by this paper
• Lineage relationship and protective immunity of memory CD8 T cell subsets

  2003cited by this paper
• Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine.

  2003cited by this paper
• Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.

  2003cited by this paper
• Current developments in cancer vaccines and cellular immunotherapy.

  2003cited by this paper
• Prime-boost strategies for malaria vaccine development

  2003cited by this paper
• Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response.

  2003cited by this paper
• Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.

  2003cited by this paper
• Individual Analysis of Mice Vaccinated against a Weakly Immunogenic Self Tumor-Specific Antigen Reveals a Correlation between CD8 T Cell Response and Antitumor Efficacy 1

  2003cited by this paper
• Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles.

  2003cited by this paper
• Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity.

  2002cited by this paper
• Intensity of the Vaccine-Elicited Immune Response Determines Tumor Clearance

  2002cited by this paper
• Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols1

  2002cited by this paper
• Vaccination with Recombinant Alphavirus or Immune-Stimulating Complex Antigen Against Respiratory Syncytial Virus1

  2002cited by this paper
• Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus.

  2001cited by this paper
• Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.

  2001cited by this paper
• Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (alvac) cytokine gene delivery induces destruction of established prostate tumors

  2001cited by this paper
• The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.

  2001cited by this paper
• Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.

  2000cited by this paper
• Recombinant viruses as a tool for therapeutic vaccination against human cancers.

  2000cited by this paper
• Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.

  2000cited by this paper
• T Cells Compete for Access to Antigen-Bearing Antigen-Presenting Cells

  2000cited by this paper
• Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

  1999influential reference
• Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.

  1999cited by this paper
• Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex

  1999cited by this paper
• Two-Helper RNA System for Production of Recombinant Semliki Forest Virus Particles

  1999cited by this paper
• Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene

  1999cited by this paper
• Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice.

  1999cited by this paper
• Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

  1998influential reference
• The shared tumor‐specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection

  1998cited by this paper
• Enhancing immune responses using suicidal DNA vaccines

  1998cited by this paper
• High expression of MAGE‐3 protein in squamous‐cell lung carcinoma

  1997cited by this paper
• The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A‐encoded tumor antigen

  1997cited by this paper
• Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.

  1997cited by this paper
• The three-dimensional structure of an H-2Ld-peptide complex explains the unique interaction of Ld with beta-2 microglobulin and peptide.

  1997cited by this paper
• Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.

  1997cited by this paper
• Human tumor antigens recognized by T lymphocytes

  1996cited by this paper
• Induction of a cytolytic T‐cell response in mice with a recombinant adenovirus coding for tumor antigen P815A

  1996cited by this paper
• Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro.

  1995cited by this paper
• Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus.

  1995cited by this paper
• Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes

  1995cited by this paper
• Tumor antigens recognized by T lymphocytes.

  1994cited by this paper
• Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

  1994cited by this paper
• Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes

  1994cited by this paper
• A New Generation of Animal Cell Expression Vectors Based on the Semliki Forest Virus Replicon

  1991cited by this paper
• A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

  1991cited by this paper
• The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice

  1991cited by this paper
• Selection of highly transfectable variant from mouse mastocytoma P815

  1985influential reference
• Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression

  1983cited by this paper
• A functional comparison of tumor cell killing by activated macrophages and natural killer cells

  1979cited by this paper
• A transplantable mast-cell neoplasm in the mouse.

  1957cited by this paper

• Novel H-2Db-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice

  2024cites this paper
• Channeling the Natural Properties of Sindbis Alphavirus for Targeted Tumor Therapy

  2023cites this paper
• Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy

  2021cites this paper
• TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism

  2021cites this paper
• Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination.

  2020cites this paper
• Current Advances in Burkholderia Vaccines Development

  2020cites this paper
• Optimizing oncolytic virotherapy in cancer treatment

  2019cites this paper
• Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

  2018cites this paper
• Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

  2018cites this paper
• Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen

  2018cites this paper
• Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens

  2018cites this paper
• An alphavirus-based therapeutic cancer vaccine: from design to clinical trial

  2018cites this paper
• Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes

  2017cites this paper
• Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines

  2017influential citation
• Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells

  2017cites this paper
• Microneedle-mediated delivery of viral vectored vaccines

  2017cites this paper
• Codon-Optimized P1A-Encoding DNA Vaccine: Toward a Therapeutic Vaccination against P815 Mastocytoma

  2017cites this paper
• THE PRECLINICAL DEVELOPMENT OF ONCOLYTIC VIRAL IMMUNOTHERAPY FOR EPITHELIAL CANCER

  2017cites this paper
• Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy.

  2017cites this paper
• Preclinical and clinical development of DNA vaccines for prostate cancer.

  2016cites this paper
• Self-replicating alphavirus RNA vaccines

  2015cites this paper
• The site of administration influences both the type and the magnitude of the immune response induced by DNA vaccine electroporation.

  2015cites this paper
• Malaria Transmission Blocking Vaccines

  2015cites this paper
• Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations.

  2015cites this paper
• Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion

  2015cites this paper
• Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy

  2015cites this paper
• Human Tumor Antigens and Cancer Immunotherapy

  2015cites this paper
• Kinetic and Phenotypic Analysis of CD8+ T Cell Responses after Priming with Alphavirus Replicons and Homologous or Heterologous Booster Immunizations

  2014cites this paper
• Going viral with cancer immunotherapy

  2014cites this paper
• Intramuscular electroporation of a P1A-encoding plasmid vaccine delays P815 mastocytoma growth.

  2014cites this paper
• Experimental Glioma Forest Virus and Vaccinia Virus, in Neurotropic Oncolytic Viruses, Semliki Resistance to Two Heterologous

  2014cites this paper
• Novel Technologies for Vaccine Development

  2014cites this paper
• Adenovirus-Based Vectors for the Development of Prophylactic and Therapeutic Vaccines

  2014cites this paper
• Alphavirus replicon-based strategies for vaccination

  2014cites this paper
• Therapeutic vaccines for cancer: an overview of clinical trials

  2014cites this paper
• Evolution of oncolytic viruses: novel strategies for cancer treatment.

  2013cites this paper
• The Adjuvant Activity of Alphavirus Replicons Is Enhanced by Incorporating the Microbial Molecule Flagellin into the Replicon

  2013cites this paper
• Vaccination studies with the mper of HIV-1 gp41 grafted into transmembrane protein of a gammaretrovirus

  2013cites this paper
• Viral vectors for vaccine applications

  2013cites this paper
• Malaria vaccines: focus on adenovirus based vectors.

  2012cites this paper
• Lentiviral vector followed by protein immunisation breaks tolerance against the self‐antigen Her1 and results in lung cancer immunotherapy

  2012cites this paper
• Advances and Future Challenges in Recombinant Adenoviral Vectored H5N1 Influenza Vaccines

  2012cites this paper
• Resistance to Two Heterologous Neurotropic Oncolytic Viruses, Semliki Forest Virus and Vaccinia Virus, in Experimental Glioma

  2012cites this paper
• Prime‐boost vaccinations using recombinant flavivirus replicon and vaccinia virus vaccines: an ELISPOT analysis

  2011cites this paper
• Oncolytic viruses: a step into cancer immunotherapy

  2011cites this paper
• Baculovirus Capsid Display Potentiates OVA Cytotoxic and Innate Immune Responses

  2011cites this paper
• Emerging Cancer Vaccines: The Promise of Genetic Vectors

  2011cites this paper
• The Role of CD8+ T Cell Phenotype and Cytotoxicity on Cancer Immunotherapy

  2011cites this paper
• Virus Adaptation and Treatment Oncolytic viruses : a step into cancer immunotherapy

  2011cites this paper
• Combining Oncolytic Viruses with Cancer Immunotherapy

  2011cites this paper
• Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens.

  2010cites this paper
• Combining oncolytic virotherapy and tumour vaccination.

  2010cites this paper
• The Immunosuppressive Tumor Environment Is the Major Impediment to Successful Therapeutic Vaccination in Neu Transgenic Mice

  2010cites this paper
• Alphavirus vectors for cancer therapy.

  2010cites this paper
• A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice.

  2010cites this paper
• Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations

  2010cites this paper
• Archaeosome Adjuvant Overcomes Tolerance to Tumor-Associated Melanoma Antigens Inducing Protective CD8+ T Cell Responses

  2010cites this paper
• Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.

  2009cites this paper
• Viral vectors, in innate and adaptive immunity

  2009cites this paper
• Intracellular bacterial vectors that induce CD8(+) T cells with similar cytolytic abilities but disparate memory phenotypes provide contrasting tumor protection.

  2009cites this paper
• Investigation of the Vaccine Potential of Different Semliki Forest Virus Based Vectors

  2009cites this paper
• Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.

  2009cites this paper
• Provide Contrasting Tumor Protection Phenotypes Similar Cytolytic Abilities but Disparate Memory T Cells with + Intracellular Bacterial Vectors That Induce CD8

  2009cites this paper
• Vacinação com a proteína 2 da superfície de amastigotas contra a infecção experimental pelo Trypanosoma cruzi: eficácia de diferentes estratégias vacinais e mecanismos de imunidade

  2009cites this paper
• Impact of Preexisting Vector-Specific Immunity on Vaccine Potency: Characterization of Listeria monocytogenes-Specific Humoral and Cellular Immunity in Humans and Modeling Studies Using Recombinant Vaccines in Mice

  2009cites this paper
• Immunization with a recombinant fowlpox virus expressing a hepatitis C virus core–E1 polyprotein variant, protects mice and African green monkeys (Chlorocebus aethiops sabaeus) against challenge with a surrogate vaccinia virus

  2008cites this paper
• Viral vectors in cancer immunotherapy: which vector for which strategy?

  2008cites this paper
• Evaluation of new strategies to elicit neutralizing antibodies against HIV-1

  2008cites this paper
• Novel immunotherapeutic strategies for gynaecologic malignancies

  2008cites this paper
• EVALUATION OF NEW STRATEGIES TO STIMULATE NEUTRALIZING ANTIBODIES AGAINST HIV-1

  2008cites this paper